

SUPPLEMENTAL REFERENCES

1. Hayden, A., Johnson, P.W., Packham, G., and Crabb, S.J. (2011). S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. *Breast cancer research and treatment* *127*, 109-119.
2. Kemp, C.D., Rao, M., Xi, S., Inchauste, S., Mani, H., Fetsch, P., Filie, A., Zhang, M., Hong, J.A., Walker, R.L., et al. (2012). Polycomb repressor complex-2 is a novel target for mesothelioma therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research* *18*, 77-90.
3. Smits, M., Mir, S.E., Nilsson, R.J., van der Stoop, P.M., Niers, J.M., Marquez, V.E., Cloos, J., Breakefield, X.O., Krichevsky, A.M., Noske, D.P., et al. (2011). Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. *PLoS One* *6*, e16282.
4. Suva, M.L., Riggi, N., Janiszewska, M., Radovanovic, I., Provero, P., Stehle, J.C., Baumer, K., Le Bitoux, M.A., Marino, D., Cironi, L., et al. (2009). EZH2 is essential for glioblastoma cancer stem cell maintenance. *Cancer research* *69*, 9211-9218.
5. Kim, K.H., and Roberts, C.W. (2016). Targeting EZH2 in cancer. *Nat Med* *22*, 128-134.
6. Knutson, S.K., Wigle, T.J., Warholc, N.M., Sneeringer, C.J., Allain, C.J., Klaus, C.R., Sacks, J.D., Raimondi, A., Majer, C.R., Song, J., et al. (2012). A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. *Nature chemical biology* *8*, 890-896.
7. Knutson, S.K., Kawano, S., Minoshima, Y., Warholc, N.M., Huang, K.C., Xiao, Y., Kadowaki, T., Uesugi, M., Kuznetsov, G., Kumar, N., et al. (2014). Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. *Molecular cancer therapeutics* *13*, 842-854.
8. Knutson, S.K., Warholc, N.M., Wigle, T.J., Klaus, C.R., Allain, C.J., Raimondi, A., Porter Scott, M., Chesworth, R., Moyer, M.P., Copeland, R.A., et al. (2013). Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. *Proc Natl Acad Sci U S A* *110*, 7922-7927.
9. Verma, S.K., Tian, X., LaFrance, L.V., Duquenne, C., Suarez, D.P., Newlander, K.A., Romeril, S.P., Burgess, J.L., Grant, S.W., Brackley, J.A., et al. (2012). Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. *ACS medicinal chemistry letters* *3*, 1091-1096.
10. Zingg, D., Debbache, J., Schaefer, S.M., Tuncer, E., Frommel, S.C., Cheng, P., Arenas-Ramirez, N., Haeusel, J., Zhang, Y., Bonalli, M., et al. (2015). The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. *Nature communications* *6*, 6051.
11. McCabe, M.T., Ott, H.M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G.S., Liu, Y., Graves, A.P., Iii, A.D.P., Diaz, E., et al. (2012). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. *Nature* *492*, 108-112.
12. Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., Zeng, J., Li, M., Fan, H., Lin, Y., et al. (2012). Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. *Proc Natl Acad Sci U S A* *109*, 21360-21365.

13. Bradley, W.D., Arora, S., Busby, J., Balasubramanian, S., Gehling, V.S., Nasveschuk, C.G., Vaswani, R.G., Yuan, C.C., Hatton, C., Zhao, F., et al. (2014). EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. *Chemistry & biology* 21, 1463-1475.
14. Medicine, U.N.L.o. (2015). ClinicalTrials.gov <https://clinicaltrials.gov/ct2/show/NCT02395601>.
15. Comet, I., Riising, E.M., Leblanc, B., and Helin, K. (2016). Maintaining cell identity: PRC2-mediated regulation of transcription and cancer. *Nature reviews. Cancer*.
16. Konze, K.D., Ma, A., Li, F., Barsyte-Lovejoy, D., Parton, T., Macnevin, C.J., Liu, F., Gao, C., Huang, X.P., Kuznetsova, E., et al. (2013). An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. *ACS chemical biology* 8, 1324-1334.